在肺癌的发展过程中，由于缺乏有效的肿瘤分子标志物的早期筛查和诊断，临床

During the development of lung cancer, due to the lack of effective early screening and diagnosis of tumor molecular markers, most of the clinically diagnosed lung cancer patients are advanced patients, resulting in patients missing the best treatment opportunity and significantly reducing the survival rate. A large number of studies have shown that miRNA exists in the blood of lung cancer patients, and it is expected that high-throughput sequencing will screen out early lung cancer biomarker molecules for early diagnosis and treatment of lung cancer. Analysis of miRNA with different expression levels helps us understand the pathogenesis of lung cancer and clarify the role of miRNA in lung cancer. According to the previous high-throughput sequencing data of our group, the genome-wide miRNA expression levels of lung cancer tissues and normal lung tissues were compared and verified in the TCGA database to determine miR-20b as the research object. In this chapter, we studied the expression of miR-20b in the plasma and lung cancer cell lines of patients with non-small cell lung cancer.

In the development of lung cancer, due to the lack of early screening and diagnosis of effective tumor molecular markers, most of the patients with clinically diagnosed lung cancer are advanced patients, resulting in patients missing the best treatment opportunity, so that the survival rate is significantly reduced. Numerous studies have shown that miRNA is present in the blood of lung cancer patients, and it is hoped that early lung cancer biomarkers can be screened through high-throughput sequencing for early diagnosis and treatment of lung cancer. MiRNA analysis at different levels of expression helps us understand the pathogenesis of lung cancer and illustrates the role of miRNA in lung cancer. Based on previous high-throughput sequencing data from our group, the whole genome miRNA expression levels of lung cancer tissue and normal lung tissue were compared and validated in the TCGA database to identify miR-20b as the subject of the study. In this chapter, we study the expression of miR-20b in plasma and lung cancer cell lines in patients with non-small cell lung cancer.

In the development of lung cancer, due to the lack of effective early screening and diagnosis of tumor molecular markers, most of the patients with clinically confirmed lung cancer are late patients, which leads to the patients missing the best opportunity for treatment and significantly reducing the survival rate. A large number of studies have shown that miRNA exists in the blood of lung cancer patients, which is expected to screen biomarkers of early lung cancer through high-throughput sequencing for early diagnosis and treatment of lung cancer. MiRNA analysis of different expression levels can help us to understand the pathogenesis of lung cancer and clarify the role of miRNA in lung cancer. According to our previous high-throughput sequencing data, we compared the whole genome miRNA expression level of lung cancer and normal lung tissues, and verified it in TCGA database, and determined mir-20b as the research object. In this chapter, we studied the expression of mir-20b in plasma and lung cancer cell lines of NSCLC patients.<br>